For the Inventor, By the Inventor

Enter assignee name

Lawrence, KS, United States of America

Crititech, Inc.

Calculating rank

USPTO Granted Patents = 33

% Expired Patents = 3.0

EPO Patents = 12

Trademarks = 1

Forward Citations = 260

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

Michael Baltezor (21 out of 21 patents)

Matthew McClorey (18 out of 18 patents)

Gere S diZerega (14 out of 15 patents)

4. Joseph S Farthing (13 out of 13 patents)

5. Charles J Decedue (13 out of 14 patents)

6. Sam Campbell (12 out of 14 patents)

7. Mark D Williams (11 out of 12 patents)

8. Jahna Espinosa (9 out of 9 patents)

9. Jacob M Sittenauer (8 out of 8 patents)

10. Bala Subramaniam (7 out of 63 patents)

11. Jake Sittenauer (6 out of 6 patents)

12. Samuel Campbell (6 out of 6 patents)

13. Julia K Fischer (6 out of 6 patents)

14. Gary E Clapp (6 out of 6 patents)

15. Mike Baltezor (5 out of 6 patents)

Core Competencies:

Solid Tumor Treatment

Antineoplastic Particles

Immunotherapeutic Agents

Particle Delivery

Epithelial Cysts

Nintedanib

Niraparib

Rucaparib

Taxane

Ciprofloxacin

Lung Disorders

Poorly Water Soluble Drugs

33 patents: Sort by Forward Citations

1. 12390459 - Methods for solid tumor treatment (2025-08-19),

2. 12329858 - Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer (2025-06-17),

3. 12128131 - Treatment of epithelial cysts by intracystic injection of antineoplastic particles (2024-10-29),

4. 12029818 - Lapatinib particles and uses thereof (2024-07-09),

5. 11931368 - Glucocorticoid 'nintedanib' particles and their use (2024-03-19),

6. 11918691 - Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer (2024-03-05),

7. 11738029 - Rucaparib particles and uses thereof (2023-08-29),

8. 11738014 - Niraparib particles and uses thereof (2023-08-29),

9. 11737972 - Treatment of epithelial cysts by intracystic injection of antineoplastic particles (2023-08-29),

10. 11583499 - Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer (2023-02-21),

11. 11523983 - Treatment of epithelial cysts by intracystic injection of antineoplastic particles (2022-12-13),

12. 11458133 - Methods for solid tumor treatment (2022-10-04),

13. 11291646 - Nozzle assembly and methods for use (2022-04-05),

14. 11160754 - Methods for treating lung disorders (2021-11-02),

15. 11123322 - Taxane particles and their use (2021-09-21),

Company Overview

Crititech, Inc. is a technology company based in Lawrence, Kansas, specializing in the development of innovative solutions for critical applications in various industries. The organization focuses on advanced materials and engineering processes, particularly in the realm of medical devices and diagnostics. With a commitment to enhancing performance and reliability, Crititech leverages its expertise to address complex challenges, contributing to advancements in healthcare and other sectors through cutting-edge research and development.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

33 Patents

#4 in Lawrence, KS

#71 in Kansas

#10,327 in US

#20,211 in the World

Lawrence, KS, United States of America

Crititech, Inc.

Forward Citations = 260

30 inventors:

Michael Baltezor (21 out of 21 patents)

Matthew McClorey (18 out of 18 patents)

Gere S diZerega (14 out of 15 patents)

4. Joseph S Farthing (13 out of 13 patents)

5. Charles J Decedue (13 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Crititech, Inc.. Retrieved from https://idiyas.com/company/crititech

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…